# Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

> **NCT01834014** · NA · COMPLETED · sponsor: **EPS Corporation** · enrollment: 110 (actual)

## Conditions studied

- Liver Metastasis
- Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab
- **DRUG:** L-OHP
- **DRUG:** l-LV
- **DRUG:** 5-FU
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT01834014
- **Lead sponsor:** EPS Corporation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01834014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01834014, "Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01834014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*